Bluebird Looks to Raise $250M After Lukewarm Reception of SCD Gene Therapy

Bluebird bio on Monday announced that it is accessing two funding opportunities that could potentially bump up its cash position by a total of $250 million.

The first is an underwritten public offering in which the Massachusetts-based biotech plans to put shares of its common stock up for sale, seeking to raise $150 million. The offering also includes a 30-day option for underwriters to buy up to an additional $22.5 million of bluebird shares.